Major AlphaFold upgrade offers boost for drug discovery

nature.com · 539 words · saved by 1 readers

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript. Advertisement You can also search for this author in PubMed Google Scholar You have full access to this article via University of California, Berkeley Nature Masterclasses An AlphaFold3 model of a bacterial enzyme bound to a chemical.Credit: Isomorphic Labs Since the powerhouse artificial intelligence (AI) tool AlphaFold2 was released in 2021, scientists have used the protein-structure-prediction model to map one of our cells’ biggest machines, discover drugs and chart the universe of every known protein. Despite such successes, John Jumper — who leads AlphaFold’s development at Google

Email Bluesky Facebook LinkedIn Reddit Whatsapp X Access through your institution Buy or subscribe Since the powerhouse artificial intelligence (AI) tool AlphaFold2 was released in 2021, scientists have used the protein-structure-prediction model to map one of our cells’ biggest machines, discover drugs and chart the universe of every known protein. Access options Access through your institution Access Nature and 54 other Nature Portfolio journals Get Nature+, our best-value online-access subscription $32.99 / 30 days cancel any time Learn more Subscribe to this journal Receive 52 print issues

Major AlphaFold upgrade offers boost for drug discovery

related reading